Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses TCRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TCRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gavin MacBeath | $665,000 | $0 | $0 | $1,982,800 | $139,650 | $0 | $14,000 | $2,801,450 |
| Chief Executive Officer and Director | ||||||||
| Chrystal Louis | 530,000 | 0 | 0 | 991,400 | 74,200 | 0 | 14,000 | 1,609,600 |
| Chief Medical Officer | ||||||||
| Jason Amello | 520,000 | 0 | 0 | 669,195 | 72,800 | 0 | 14,000 | 1,275,995 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gavin MacBeath | $2,801,450 | — | — | — |
| Chrystal Louis | 1,609,600 | — | — | — |
| Jason Amello | 1,275,995 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | 2026-05-20 | A | 67,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| R. Keith Woods | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gabriela Gruia | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katina Dorton | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barbara Klencke | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chrystal Louis | OPTION | 2025-01-03 | — | — | 400,000 | — | $994,825 |
| Gavin MacBeath | OPTION | 2025-01-03 | — | — | 800,000 | — | 1,989,651 |
| Jason Amello | OPTION | 2025-01-03 | — | — | 270,000 | — | 671,507 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chrystal Louis | $0 | $0 | $994,825 | 0.0% |
| Gavin MacBeath | 0 | 0 | 1,989,651 | 0.0% |
| Jason Amello | 0 | 0 | 671,507 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gavin MacBeath | Option | 11,667 | 1.81 | — |
| Gavin MacBeath | Option | 83,334 | 6 | — |
| Jason Amello | Option | 390,625 | 5.15 | — |
| Gavin MacBeath | Option | 14,584 | 3.27 | — |
| Gavin MacBeath | Option | 316,875 | 2.49 | — |
| Chrystal Louis | Option | 400,000 | 3.07 | — |
| Jason Amello | Option | 270,000 | 3.07 | — |
| Gavin MacBeath | Option | 189,940 | 2.49 | — |
| Gavin MacBeath | Option | 2,917 | 4.85 | — |
| Chrystal Louis | Option | 221,667 | 8.62 | — |
| Gavin MacBeath | Option | 800,000 | 3.07 | — |
TScan's compensation program is designed to attract and retain highly qualified named executive officers by providing competitive base salaries, performance-based annual cash incentive bonuses tied to corporate and individual goals, and long-term equity incentives in the form of stock options to align executive interests with stockholder value creation. The company does not generally provide perquisites or personal benefits beyond standard health and welfare plans available to all employees.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen Biggar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Research and Clinical Development | $90,609 | $0 | $71,623 | $0 | $0 | $162,232 |
| Barbara Klencke, M.DIndependent · Audit · Compensation · Research and Clinical Development (Chair) | 74,156 | 0 | 71,623 | 0 | 0 | 145,779 |
| Katina Dorton, J.D., M.B.AIndependent · Audit (Chair) · Compensation · Nominating/Governance | 67,486 | 0 | 71,623 | 0 | 0 | 139,109 |
| Gabriela Gruia, M.DIndependent · Audit · Nominating/Governance · Research and Clinical Development | 57,499 | 0 | 71,623 | 0 | 0 | 129,122 |
| Garry NicholsonIndependent · Nominating/Governance (Chair) · Research and Clinical Development | 53,740 | 0 | 71,623 | 0 | 0 | 125,363 |
| R. Keith WoodsIndependent · Audit · Compensation | 53,642 | 0 | 71,623 | 0 | 0 | 125,265 |
| Gavin MacBeath, Ph.DEmployee director · Research and Clinical Development | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $71,623 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $397,132 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $397,132 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TScan Therapeutics, Inc. | 2025 | Gavin MacBeath | $665,000 | $0 | $1,982,800 | $139,650 | $2,801,450 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gavin MacBeath | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387 |
| 2 | Section 01, Chrystal Louis | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 1,609,600. Filing ↗machine: t40 · r6 · c27 · span 229201–229210 |
| 3 | Section 01, Jason Amello | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 1,275,995. Filing ↗machine: r4 · c27 · span 224738–224747 |
| 4 | Section 03, Chrystal Louis OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 5 | Section 03, Gavin MacBeath OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 6 | Section 03, Jason Amello OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 7 | Section 07, pay ratio | 10-K | 2026-03-04 | 0001193125-26-089884 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Stephen Biggar, M.D., Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 162,232. Filing ↗machine: t54 · r2 · c11 · span 304325–304332 |
| 9 | Section 08, Barbara Klencke, M.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 145,779. Filing ↗machine: t54 · r5 · c11 · span 307586–307593 |
| 10 | Section 08, Katina Dorton, J.D., M.B.A | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 139,109. Filing ↗machine: t54 · r3 · c11 · span 305408–305415 |
| 11 | Section 08, Gabriela Gruia, M.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 129,122. Filing ↗machine: t54 · r4 · c11 · span 306509–306516 |
| 12 | Section 08, Garry Nicholson | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 125,363. Filing ↗machine: t54 · r7 · c11 · span 309752–309759 |
| 13 | Section 08, R. Keith Woods | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 125,265. Filing ↗machine: t54 · r6 · c11 · span 308681–308688 |
| 14 | Section 08, Gavin MacBeath, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, BAKER BROS. ADVISORS LP 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236870 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Garry Nicholson 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236854 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, R. Keith Woods 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236855 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Gabriela Gruia 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236848 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Katina Dorton 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236844 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Barbara Klencke 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236841 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, BAKER BROS. ADVISORS LP 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236870 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 23 | Section 09b board cost (computed) | Computed | — | computed | Cash 397,132 + equity 0 + all other 0 = 397,132, summed across the director compensation table rows.machine: formula: Σ = 397,132 |
| 24 | TScan Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160304 | CEO total compensation as printed in TScan Therapeutics, Inc.'s own proxy. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387 |